CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Patrys Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Patrys Ltd
Level 4, 96-100 Albert Road
Phone: +61 396703273p:+61 396703273 SOUTH MELBOURNE, VIC  3205  Australia Ticker: PABPAB
Business Summary
Patrys Limited is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different cancers. The Company’s deoxymab platform is based on the deoxymab 3E10 antibody that is identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus (SLE). It has developed two humanized forms of deoxymab 3E10, both have improved activity over the original deoxymab 3E10 antibody. PAT-DX1 is a dimer (two joined subunits) of the short chain from the binding domain of deoxymab 3E10, while PAT-DX3 is a full-sized IgG antibody. In a range of pre-clinical studies, PAT-DX1 has shown an ability to kill cancer cells in cell models, human tumor explants, xenograft and orthotopic models. Deoxymabs, such as PAT-DX1 and PAT-DX3, can be used to target nanoparticles carrying a payload of anti-cancer drugs specifically to tumors. This allows specific delivery of cancer drugs to multiple types of cancer.
(Source: 10KSB40)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20246/30/2024Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board CharmaineGittleson 11/16/2022 11/16/2022
Chief Executive Officer, Managing Director, Executive Director James A.Campbell 4/13/2015 11/12/2014
Non-Executive Deputy Chairman of the Board MichaelStork 11/16/2022 2/19/2007
4 additional Officers and Directors records available in full report.

Business Names
Business Name
Nucleus Therapeutics Pty Ltd
PAB
Patrys Limited

General Information
Number of Employees: 15 (As of 6/30/2014)
Outstanding Shares: 2,055,750,236 (As of 6/30/2024)
Shareholders: 3,310
Stock Exchange: ASX
Fax Number: +61 396703247


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024